Changes to our Gastrointestinal Microbiome Offerings

On behalf of Invivo Healthcare, I’d like to address a recent change to our gastrointestinal microbiome offerings. Invivo no longer sell the GI-MAP, we now only offer GI EcologiX as our clinical tool to assess the gastrointestinal microbiome.


On behalf of Invivo Healthcare, I’d like to address a recent change to our gastrointestinal microbiome offerings. Invivo no longer sell the GI-MAP, we now only offer GI EcologiX as our clinical tool to assess the gastrointestinal microbiome.

Over the last decade, we have been pioneering the most advanced methodologies in clinical microbiome assessments. We have led the way in clinical applications of microbiome research and strive to do so for the next decade. To be able to achieve this we founded Phylo Bioscience Laboratory in Bristol. This will allow us to pursue clinical excellence in both commercial testing and exciting research projects, which in turn will benefit both you and your patients.

Phylo Bioscience has worked with a global consultancy of thought leaders, researchers, and clinicians in the design of the EcologiX profiles. With their guidance, we developed three profiles focused on assessing chronic disease pathologies, as opposed to acute care ones. In the development of our new GI EcologiX test, we were able to change markers that had little clinical data and those with limited clinical relevance for the UK and European market. To ensure we created an accessibly priced clinical tool, we removed markers that can be assessed in the NHS in an acute medical condition. We also re-evaluated certain host health markers where sample stability or methodology did not stand up to our rigorous standards.

In doing so, we were able to introduce new markers with significant research associated with chronic health conditions whether via SCFA production, oxalate degradation, hydrogen sulfide production, enterotoxin expression and/or clinical associations with conditions such as IBS, IBD, CRC, autoimmunity, and neurodegeneration.

Phylo Bioscience is also Care Quality Commission (CQC) registered, which is the independent regulator of healthcare and adult social care services in England. We are registered to provide both diagnostic and screening services. Their rigorous assessments ensure our service meets government standards of quality and safety. Our regulation sees us join the NHS and private hospitals, GP’s and laboratories, who are all required to obtain CQC regulation.

The Bristol-based laboratory furthers our commitment to our environmental and ethical goals, as well as the standards of transparency and responsible business that are expected by us through our B Corp and Carbon Neutral certifications.

We trust our science, our team, and our service. These profiles, including GI EcologiX, are born from a collaboration between a team with over 125 years’ experience in the field. I truly believe we have created world-class microbiome profiles that you can trust and rely on for your patients and their health outcomes. And in our Clinical Education team, you have a support network to help you navigate the results, for best patient outcomes.

Thank you

Humphrey Bacchus
MD Invivo Healthcare | Founder Phylo Bioscience

Related Articles


Bio.Me, Bio.Me Barrier, Gastrointestinal
Looking for a product to support gut barrier function?

When is barrier function a relevant clinical consideration? The importance of an effective physical and immune barrier at the site of host-microbiome interactions cannot be downplayed. Our solution is Bio....

Bio.Clear, Gastrointestinal, Microbiome
New Bio.Clear™ Microbia GI

Our new anti-microbial botanical blend for dysbiotic microbiome(s)

Female EcologiX™, Gastrointestinal, GI EcologiX™, Microbiome, Oral EcologiX™
The Science Behind The EcologiX™ Profiles

The methodology, quality and accuracy measures behind the EcologiX™ profiles, and the importance of pattern and context recognition.